-+ 0.00%
-+ 0.00%
-+ 0.00%

Travere gets USPTO notice of allowance for FILSPARI use in FSGS patent application

PUBT·09/23/2026 11:03:06
Travere gets USPTO notice of allowance for FILSPARI use in FSGS patent application
  • Travere received a USPTO notice of allowance for a U.S. patent application covering methods of using FILSPARI (sparsentan) in FSGS.
  • Once issued, the patent is expected to extend U.S. method-of-use coverage for sparsentan in FSGS into October 2037.
  • Travere plans to list the patent in the FDA’s Orange Book following grant.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609230700BIZWIRE_USPR_____20260923_BW592621) on September 23, 2026, and is solely responsible for the information contained therein.